Research Progress on Tyrosine Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2025.01.046
- Author:
Jun-Xia HE
1
;
Xi-Yuan JIANG
1
;
Ya-Ming XI
2
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000， Gansu Province， China.
2. Department of Hematology， The First Hospital of Lanzhou University， Lanzhou 730000， Gansu Province， China.
- Publication Type:English Abstract
- Keywords:
Chronic myeloid leukemia;
treatment discontinuation;
tyrosine kinase inhibitors；treatment free remission
- MeSH:
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Protein Kinase Inhibitors/therapeutic use*;
Remission Induction;
Tyrosine Kinase Inhibitors
- From:
Journal of Experimental Hematology
2025;33(1):300-305
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of patients with chronic myeloid leukemia (CML), and achieving treatment-free remission (TFR) has become a new goal for these patients. Various methods of discontinuing medication are continuously being explored, with successful cessation linked to factors such as the duration of TKI treatment, the sustainability of deep molecular response (DMR), transcript type, and immunological factors. Early switching of TKI, combining other therapies, and targeting leukemia stem cells may help increase the TFR rate. This article reviews the latest research developments on the exploration of TKI cessation, factors affecting TFR, selection of patients for discontinuation, strategies to enhance TFR, and monitoring after cessation, expecting to provide reference and guidance for achieving TFR in CML patients.
